MetLife (MET) director acquires 48 shares via dividend reinvestment

MetLife, Inc. (MET) director Jeh C. Johnson reported a small non-derivative acquisition of company stock.

Rhea-AI Filing Summary

MetLife, Inc. (MET) director Jeh C. Johnson reported a small non-derivative acquisition of company stock. The Form 4 shows an imputed reinvestment of dividends under the MetLife Deferred Compensation Plan for Non-Management Directors, resulting in an acquisition of 48 shares on 09/09/2025 at an imputed price of $79.29 per share. Following the transaction, the reporting person beneficially owned 6,838 shares. The filing was signed by an attorney-in-fact on 09/11/2025. The disclosure reflects a routine dividend reinvestment rather than an open-market purchase or exercise of options.

Positive

• Increased insider ownership: Reporting person beneficially owns 6,838 shares after the reinvestment, modestly increasing alignment with shareholders
• Proper disclosure: Transaction reported on Form 4 and signed by attorney-in-fact, demonstrating compliance with Section 16 reporting requirements

Negative

• None.

Insights

Financial Analyst

Routine dividend reinvestment; immaterial to valuation but increases insider stake modestly.

The reported 48-share acquisition is the result of dividend reinvestment under the company plan, not an active market trade. At $79.29 implied price, the transaction increases the director's direct holdings to 6,838 shares, a small change relative to typical institutional positions. There are no derivative exercises, sales, or other actions that would signal a change in insider sentiment or corporate control.

Corporate Governance Expert

Disclosure meets Section 16 reporting standards; transaction appears procedural and non-material.

The Form 4 documents an imputed dividend reinvestment under the deferred compensation plan for non-management directors. Signature by an attorney-in-fact is noted. The filing aligns with standard insider reporting obligations and does not indicate any governance or compliance issues based on the provided information.

Insider Trade Summary

Grant/Award: 48 shares

Grant/Award 1 txn

Insider Johnson Jeh C.

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	48	$79.29	$4K

Holdings After Transaction: Common Stock — 6,838 shares (Direct)

Footnotes (1)

1. F1. Imputed reinvestment of dividends on deferred shares pursuant to the MetLife Deferred Compensation Plan for Non-Management Directors. Deferred shares represent shares of MetLife, Inc. common stock that have become payable, but receipt of which the director has deferred.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What transaction did MetLife director Jeh C. Johnson report on Form 4 (MET)?

The Form 4 reports an imputed reinvestment of dividends that resulted in the acquisition of 48 shares on 09/09/2025 at an imputed price of $79.29 per share.

How many MetLife (MET) shares does the reporting person own after the transaction?

After the reported transaction the director beneficially owned 6,838 shares of MetLife common stock.

Was the Form 4 transaction an open-market purchase or option exercise?

No. The filing states the acquisition resulted from imputed reinvestment of dividends under the MetLife Deferred Compensation Plan for Non-Management Directors.

When was the Form 4 signed and filed for this MET transaction?

The Form displays a signature by an attorney-in-fact dated 09/11/2025 and lists the transaction date as 09/09/2025.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 09/11/2025 - 04:02 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Johnson Jeh C.

(Last) (First) (Middle)

METLIFE, INC.

200 PARK AVENUE

(Street)

NEW YORK NY 10166

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
METLIFE INC [ MET ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
09/09/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	09/09/2025		A(1)		48	A	$79.29	6,838	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Imputed reinvestment of dividends on deferred shares pursuant to the MetLife Deferred Compensation Plan for Non-Management Directors. Deferred shares represent shares of MetLife, Inc. common stock that have become payable, but receipt of which the director has deferred.

Remarks:

	/s/ Taylor McInerney Jansen, Attorney-in-fact	09/11/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.